Depo-Provera MDL Orders Explained: The Rules Behind Proof, Experts, and Resolution

The transfer order defines coordination, not liability

JPML created MDL 3140 on February 7, 2025, transferring 27 actions from eight districts to Judge M. Casey Rodgers in the Northern District of Florida and noting 41 related actions. The shared allegations concern depot medroxyprogesterone acetate products and meningioma. Centralization gathers common pretrial work before one judge. It does not certify a class, decide that a medicine caused a tumor, or assign compensation.

The court's first management orders established a master docket, leadership applications, conferences, and common discovery. Individual member cases still retain their own product history, diagnosis, timing, governing law, and defenses. A master complaint and short-form complaint reduce repeated drafting; they do not make every allegation true for every plaintiff. Readers should treat an order's procedural verb—file, serve, preserve, disclose, brief—as distinct from merits verbs such as grant judgment or admit evidence.

Direct filing changes the route, not the burden

Pretrial Order No. 10 authorized direct filing in the Northern District of Florida for MDL purposes. Without such a procedure, a plaintiff might file in another federal district and wait for transfer. Direct filing saves administrative time and can standardize complaint data. The order preserves questions that may matter if a case is later transferred or remanded, including proper venue and the law that would otherwise apply.

Direct filing is therefore not an invitation, deadline, or finding that everyone who used Depo-Provera belongs in the litigation. A filed plaintiff still has to identify the product, alleged use, injury, defendants, and claims and comply with later court orders. Statutes of limitation and repose are state-specific and fact-specific. Nothing in a general direct-filing order safely allows a public website to calculate an individual's time limit.

Threshold proof is an early documentation screen

Pretrial Order No. 17 required initial documentary proof of DMPA use and initial documentary proof of an alleged meningioma injury. The order and later deficiency process help the court identify cases missing basic support before full discovery consumes resources. Pharmacy, prescribing, administration, imaging, pathology, operative, and treatment records can serve different parts of that history depending on the facts.

Passing an initial screen is not a medical or legal causation ruling. A record can show that a person received a product and was diagnosed with a tumor without proving that one caused the other. Failing to submit required proof can have procedural consequences under later orders, but a public count does not disclose which file is deficient. Threshold proof should never be repackaged as a do-it-yourself settlement checklist.

Preemption and Rule 702 are separate gates

The defendants' preemption motion asks whether federal drug regulation forecloses specified state-law warning claims. That legal inquiry can turn on the approved label, information submitted to FDA, the manufacturer's ability to change warnings, and controlling precedent. It is not the same as deciding whether epidemiology supports a causal association. A court could resolve a legal warning theory without deciding every scientific dispute.

Rule 702 governs expert testimony. The scheduled hearing concerns whether proposed opinions use reliable methods and fit the issues the court must decide. Excluding an opinion is not a finding that a medicine is safe; admitting one is not a final verdict that it caused every tumor. Case Management Orders Nos. 10 and 11 and Pretrial Order No. 30 laid out briefing, expert depositions, pilot-case work, and how common rulings might apply across the inventory.

The June 2026 agreement order—and its limits

Pretrial Order No. 30A disclosed that plaintiffs' lead counsel and Pfizer-related defendants entered a global agreement under which plaintiffs with pending MDL cases who meet criteria agreed by the parties would have an opportunity to resolve claims. The court postponed a preemption ruling and moved the Rule 702 hearing to July 27, 2026. The public order does not attach a value matrix, name participants, publish the private criteria, or state that every pending case qualifies.

Most importantly, the order says the agreement will not resolve all MDL cases, so expert issues will proceed. Agreement, finalization, individual enrollment, release, dismissal, lien resolution, and payment are separate steps. JPML's July 1 report listed 5,830 pending actions, but that figure cannot show who may participate. The accurate public status is a disclosed resolution opportunity for qualifying pending plaintiffs alongside continuing litigation—not a universal settlement with an online calculator.

Reader questions

Frequently asked questions